

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

Paris and Boston, July 16, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on **Tuesday, July 21, 2026**.

Sacha Loiseau, Chairman and Chief Executive Officer, and **Côme de La Tour du Pin**, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.

Advance registration is required to participate in the event.

Webinar for shareholders and investors – Tuesday, July 21 2026

5:50 pm. (CEST) – French Session: [Click here to register](#)

A replay will be available for registered participants.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Mauna Kea Technologies

investors@maunakeatech.com

NewCap - Investor Relations

Thomas Grojean

+33 (0)1 44 71 94 94

maunakea@newcap.eu